-+ 0.00%
-+ 0.00%
-+ 0.00%

PRAXIS PRECISION MEDICINES - FDA EXTENDS REVIEW PERIOD FOR RELUTRIGINE NDA FOR SCN2A AND SCN8A DEES BY THREE MONTHS

Reuters·06/29/2026 20:30:00

Please log in to view news